Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 8/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429249 | 0.88 | RAB9A (0.45) | MAPTALDH1A1HPGDRAB9ALMNA | |
| SCHEMBL5440591 | 0.87 | MAPT (0.42) | MAPTALDH1A1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL5427267 | 0.86 | MAPT (0.51) | MAPTALDH1A1HPGDRAB9ALMNA | |
| SCHEMBL5439007 | 0.86 | MAPT (0.50) | MAPTALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL5429198 | 0.85 | MAPT (0.47) | MAPTALDH1A1HPGDRAB9ALMNA | |
| SCHEMBL5433193 | 0.84 | MAPT (0.57) | MAPTALDH1A1HPGDRAB9ALMNA | |
| SCHEMBL5446727 | 0.83 | MAPT (0.47) | MAPTALDH1A1HPGDRAB9ALMNA | |
| SCHEMBL5427885 | 0.82 | CYP1A2 (0.47) | MAPTRAB9ALMNAF10F2 | |
| SCHEMBL5431546 | 0.82 | F10 (0.50) | F10 | |
| SCHEMBL5432956 | 0.80 | F10 (0.38) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | PEPD, XPNPEP1, METAP1 | MAPT 4212/4885ALDH1A1 1204/4885HPGD 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.